BNP Paribas Financial Markets
IKT icon

BNP Paribas Financial Markets’s Inhibikase Therapeutics IKT Stock Holding History

BNP Paribas Financial Markets’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.2K Buy
22,744
+9,853
+76% +$17.5K ﹤0.01% 4835
2025
Q4 		$26.4K Sell
12,891
-2,749
-18% -$4.37K ﹤0.01% 4944
2025
Q3 		$25.3K Buy
15,640
+6,458
+70% +$11.2K ﹤0.01% 4848
2025
Q2 		$17.9K Buy
+9,182
New +$18K ﹤0.01% 4654

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BNP Paribas Financial Markets's IKT Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Inhibikase Therapeutics (IKT) stake by 76% in Q1 2026, buying an estimated $17.5K and bringing the position to 22,744 shares worth $38.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4835.

BNP Paribas Financial Markets first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • BNP Paribas Financial Markets held 22,744 shares of Inhibikase Therapeutics worth $38.2K as of Q1 2026.
  • BNP Paribas Financial Markets bought 9,853 Inhibikase Therapeutics shares in Q1 2026, an estimated $17.5K.
  • Inhibikase Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #4835 holding.
  • BNP Paribas Financial Markets first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.